LY4006896 is a novel therapeutic candidate developed by Eli Lilly and Company currently undergoing evaluation in a Phase 1 clinical trial for Parkinson's disease[1]. This trial represents Eli Lilly's strategic entry into Parkinson's disease drug development, expanding beyond their established Alzheimer's disease pipeline[2].
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 10 million people worldwide[3]. The disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the classic motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability[4].
| Parameter | Value |
|---|---|
| Trial ID | NCT06809400 |
| Sponsor | Eli Lilly and Company |
| Phase | Phase 1 |
| Status | Recruiting |
| Study Type | Interventional |
| Indication | Parkinson's Disease |
| Start Date | 2024 |
Phase 1 trials represent the first human testing of a new therapeutic compound and primarily focus on safety and tolerability[5]. The design typically includes:
While the specific molecular mechanism of LY4006896 remains proprietary, Eli Lilly's neuroscience division has been exploring several pathways relevant to Parkinson's disease pathogenesis:
Alpha-synuclein is a key protein implicated in Parkinson's disease pathogenesis[6]. Abnormal aggregation of alpha-synuclein into Lewy bodies represents a pathological hallmark of the disease. Therapeutic strategies targeting alpha-synuclein include:
Eli Lilly has established expertise in neuroprotective strategies through their Alzheimer's disease programs. Similar approaches may be applied to Parkinson's disease:
Mitochondrial dysfunction plays a central role in dopaminergic neuron degeneration[7]. Therapeutic targets include:
Neuroinflammation contributes to disease progression through microglial activation and cytokine release[8]. Anti-inflammatory approaches include:
Eli Lilly has built a significant neuroscience pipeline targeting neurodegenerative diseases:
| Compound | Target | Indication | Status |
|---|---|---|---|
| Donanemab | Amyloid-beta | Alzheimer's Disease | Approved |
| Remternetug | Amyloid-beta | Alzheimer's Disease | Phase 3 |
| LY4006896 | Unknown | Parkinson's Disease | Phase 1 |
The Parkinson's disease treatment landscape includes several approaches[9]:
Current Parkinson's disease treatments provide symptomatic relief but do not slow or halt disease progression. LY4006896 represents an attempt to develop disease-modifying therapies addressing:
Early-phase trials like NCT06809400 are critical for:
Parkinson's disease: clinical practice. Lancet. 2015. ↩︎
Parkinson's disease: current and future challenges. Journal of Neural Transmission. 2020. ↩︎
Neurobiology of Parkinson's disease. Nature Reviews Neuroscience. 2013. ↩︎
Neuroprotective strategies in Parkinson's disease: current landscape and future directions. Movement Disorders. 2024. ↩︎
Alpha-synuclein and the dopamine neuron. Journal of Parkinson's Disease. 2018. ↩︎
Mitochondrial dysfunction in Parkinson's disease. Nature Reviews Neurology. 2013. ↩︎
Neuroinflammation in Parkinson's disease. Progress in Neurobiology. 2019. ↩︎
Novel therapeutic targets for Parkinson's disease. Neuropharmacology. 2023. ↩︎